Cantor Fitzgerald analyst Charles Duncan maintains $Alkermes (ALKS.US)$ with a buy rating, and adjusts the target price from $48 to $43.
According to TipRanks data, the analyst has a success rate of 50.7% and a total average return of 24.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Alkermes (ALKS.US)$'s main analysts recently are as follows:
Alkermes reported third-quarter results that were generally consistent with expectations and maintained its 2024 outlook. However, the emphasis during the earnings call was on management's indication that 2025 EBITDA is anticipated to exceed $200M, contrasting with a general expectation of $400M. This discrepancy in EBITDA compared to consensus figures seems to be primarily due to the anticipated loss of high-margin royalty revenues, along with increased spending to some degree.
Alkermes' Q3 performance reflected a mix of outcomes from its existing commercial suite, which overall aligned with expectations. The company is proactively channeling its investments towards ALKS-2680 and exploring the broad possibilities presented by its orexin-2 receptor agonist pipeline. Despite the near-term influence moderating profit prospects, there is optimism regarding the long-term value generation prospects of ALKS-2680.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
坎托·菲茨杰拉德分析師Charles Duncan維持$阿爾凱默斯 (ALKS.US)$買入評級，並將目標價從48美元下調至43美元。
根據TipRanks數據顯示，該分析師近一年總勝率為50.7%，總平均回報率為24.2%。
此外，綜合報道，$阿爾凱默斯 (ALKS.US)$近期主要分析師觀點如下：
阿爾凱默斯報告的第三季度業績總體與預期一致，並保持其2024年展望。然而，在業績會上重點放在管理層表示2025年息稅折舊攤銷前利潤（EBITDA）預計將超過20000萬美元，與市場普遍預期的40000萬美元形成鮮明對比。與市場預期相比，EBITDA出現的差異似乎主要是由於高毛利版稅收入預期的流失，以及在一定程度上增加的支出。
阿爾凱默斯的第三季度表現體現出現有商業套裝的多種結果，整體與預期相符。該公司正在積極將投資導向ALKS-2680，並探索其奧雷欣-2受體激動劑管線呈現的廣泛可能性。儘管近期影響調整了利潤前景，但對ALKS-2680的長期價值創造前景持樂觀態度。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
